# Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

> **NCT05005975** · PHASE3 · RECRUITING · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 301 (estimated)

## Conditions studied

- EPP
- XLP

## Interventions

- **DRUG:** MT-7117

## Key facts

- **NCT ID:** NCT05005975
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-10
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 301 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005975, "Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05005975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*